Kineta® is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. Our company is focused on the development of novel drug candidates each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed NIH-supported research.

 

They are developing a pipeline of next-generation medicines to respond to the needs of millions of people facing diseases around the world. Their scientific areas of expertise are immunology and neuropathic pain with research directed at curbing inflammation and returning the immune system to normal function. Kineta has five unique drug programs in development and each program represents a novel mechanism-of-action and has potential to result in a new class of drug. The innovative portfolio is derived from leading edge scientific research that taps into promising recently discovered cellular channels that control the body's defense mechanisms. Kineta’s drug programs are designed to enhance or modulate the natural human immune system and show great potential to be more effective, more tolerable and confer fewer side effects than existing drugs.

 

Kineta was founded in 2008 by Drs. Charles Magness and Shawn Iadonato and it is their third biotechnology company. They are longtime business partners and highly accomplished scientists with a proven track record as entrepreneurs. Previously they led Illumigen Biosciences and successfully developed a first-in-class antiviral therapeutic in addition to several other innovative programs. In 2007 Illumigen was sold to Cubist Pharmaceuticals (NASDAQ:CBST) in a preclinical deal valued at over $340M. Drs. Magness and Iadonato are regarded as experts in translational medicine, moving drug programs from discovery phase into human clinical trials and doing so with maximum efficiency.